This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

On the Cutting Edge of HIV Care: Individualized Treatment for Improved Outcomes

On the Cutting Edge of HIV Care: Individualized Treatment for Improved Outcomes



Time to Complete

1 hour


June 29, 2018


June 29, 2019
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Albert Einstein College of Medicine

Commercial Supporter

Supported by an educational grant from Janssen Therapeutics.


Produced by Haymarket Medical Education

Program Description

The past 3 decades have seen considerable advances in antiretroviral (ART) regimens for HIV-infected individuals. Since many ART agents, combinations, and classes are now available, clinicians who treat HIV have myriad options from which to choose. However, each drug class and each individual agent is associated with its own set of advantages and disadvantages. It is critical that clinicians are knowledgeable about these factors, including the effect of HIV drug selection on patient adherence and the drug resistance and safety profiles of each agent. As new therapies for HIV are continually approved and with a growing number of new options on the horizon, clinicians must be aware of how to best utilize each potential regimen in diverse patient populations.

This educational activity uses a case-based approach to illustrate how HIV treatment should be tailored to the characteristics and needs of each patient. Considerations for selection of an initial ART regimen will be discussed, as will factors to take into account when managing the care of individuals who develop treatment resistance secondary to poor adherence, and considerations for switching virologically suppressed, treatment-experienced patients to a different regimen.

Intended Audience

Infectious disease specialists, primary care clinicians, and other health care providers who actively treat patients with HIV/AIDS.

Educational Objectives

After completing the activity, the participant should be better able to:

  • Investigate the impact of ART selection on drug resistance, safety, and adherence
  • Review the updated HHS guidelines for HIV treatment and translate the implications of key changes to actual practice
  • Implement individualized HIV treatment regimens that meet the needs of diverse patient populations

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, Albert Einstein College of Medicine and Haymarket Medical Education (HME) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.


CME Reviewer
Victor B. Hatcher, PhD

Associate Dean CME
Albert Einstein College of Medicine
Bronx, NY

Dr. Hatcher has no relevant financial relationships to disclose.

Course Director
Barry S. Zingman, MD

Medical Director, AIDS Center
Clinical Director, Infectious Diseases, Moses Division
Professor of Medicine, Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

Dr. Zingman has no relevant financial relationships to disclose.

Program Faculty
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Dr. Frank is on the advisory boards of Gilead Sciences and ViiV Healthcare.

W. David Hardy, MD, AAHIVS
Senior Director of Evidence-Based Practices
Whitman-Walker Health
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Dr. Hardy receives consulting fees from Gilead, GSK/ViiV and preforms contracted research for Amgen, CytoDyn, Gilead, GSK/ViiV, Janssen Therapeutics, and Merck.

Accredited Provider Disclosures

The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine has nothing to disclose with regard to commercial support.

Publishing Staff Disclosures

Krista Sierra and Susan Basilico of Haymarket Medical Education have nothing to disclose with regard to commercial support.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM .   Physicians should only claim those credits commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME activity will not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Janssen Therapeutics, Albert Einstein College of Medicine, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact:
For CME –


To obtain credit, a score of 70% or better on the post-test is required. Please proceed until you have successfully completed this activity and completed the post-test and evaluation, and for CME credit only, that you have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue